242 related articles for article (PubMed ID: 24088870)
1. Intravenous hemostats: challenges in translation to patients.
Lashof-Sullivan M; Shoffstall A; Lavik E
Nanoscale; 2013 Nov; 5(22):10719-28. PubMed ID: 24088870
[TBL] [Abstract][Full Text] [Related]
2. Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation.
Okamura Y; Fukui Y; Kabata K; Suzuki H; Handa M; Ikeda Y; Takeoka S
Bioconjug Chem; 2009 Oct; 20(10):1958-65. PubMed ID: 19788180
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein IIb-IIIa-liposomes bind fibrinogen but do not undergo fibrinogen-mediated aggregation.
Sloan SM; Brown EB; Liu Q; Frojmovic MM
Platelets; 2000 Mar; 11(2):99-110. PubMed ID: 10938888
[TBL] [Abstract][Full Text] [Related]
4. Intravenous hemostat: nanotechnology to halt bleeding.
Bertram JP; Williams CA; Robinson R; Segal SS; Flynn NT; Lavik EB
Sci Transl Med; 2009 Dec; 1(11):11ra22. PubMed ID: 20371456
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen γ-chain peptide-coated, ADP-encapsulated liposomes rescue thrombocytopenic rabbits from non-compressible liver hemorrhage.
Nishikawa K; Hagisawa K; Kinoshita M; Shono S; Katsuno S; Doi M; Yanagawa R; Suzuki H; Iwaya K; Saitoh D; Sakamoto T; Seki S; Takeoka S; Handa M
J Thromb Haemost; 2012 Oct; 10(10):2137-48. PubMed ID: 22905905
[TBL] [Abstract][Full Text] [Related]
6. A review of treatments for non-compressible torso hemorrhage (NCTH) and internal bleeding.
Hong C; Olsen BD; Hammond PT
Biomaterials; 2022 Apr; 283():121432. PubMed ID: 35245732
[TBL] [Abstract][Full Text] [Related]
7. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa.
Ando B; Wiedmer T; Hamilton KK; Sims PJ
J Biol Chem; 1988 Aug; 263(24):11907-14. PubMed ID: 3261296
[TBL] [Abstract][Full Text] [Related]
8. [Approaches to pre-hospital bleeding management : Current overview on civilian emergency medicine].
Lier H; Bernhard M; Knapp J; Buschmann C; Bretschneider I; Hossfeld B
Anaesthesist; 2017 Nov; 66(11):867-878. PubMed ID: 28785773
[TBL] [Abstract][Full Text] [Related]
9. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
Absar S; Nahar K; Kwon YM; Ahsan F
Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
[TBL] [Abstract][Full Text] [Related]
10. Localization of the cross-linking sites of RGD and KQAGDV peptides to the isolated fibrinogen receptor, the human platelet integrin glycoprotein IIb/IIIa. Influence of peptide length.
Calvete JJ; Schäfer W; Mann K; Henschen A; González-Rodríguez J
Eur J Biochem; 1992 Jun; 206(3):759-65. PubMed ID: 1376688
[TBL] [Abstract][Full Text] [Related]
11. Endogenous platelet fibrinogen surface expression on activated platelets.
Gralnick HR; Williams S; McKeown L; Connaghan G; Shafer B; Hansmann K; Vail M; Fenton J
J Lab Clin Med; 1991 Dec; 118(6):604-13. PubMed ID: 1744509
[TBL] [Abstract][Full Text] [Related]
12. PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery.
Zou P; Stern ST; Sun D
Pharm Res; 2014 Mar; 31(3):684-93. PubMed ID: 24065591
[TBL] [Abstract][Full Text] [Related]
13. Alternatives to allogeneic platelet transfusion.
Desborough MJ; Smethurst PA; Estcourt LJ; Stanworth SJ
Br J Haematol; 2016 Nov; 175(3):381-392. PubMed ID: 27650431
[TBL] [Abstract][Full Text] [Related]
14. Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen.
Coller BS; Kutok JL; Scudder LE; Galanakis DK; West SM; Rudomen GS; Springer KT
J Clin Invest; 1993 Dec; 92(6):2796-806. PubMed ID: 8254034
[TBL] [Abstract][Full Text] [Related]
15. The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules.
Tomiyama Y; Tsubakio T; Piotrowicz RS; Kurata Y; Loftus JC; Kunicki TJ
Blood; 1992 May; 79(9):2303-12. PubMed ID: 1373972
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of fibrinogen binding to agonist- and RGDS peptide-activated states of GPIIb-IIIa by an anti-GPIIIa monoclonal antibody, PMA5.
Nakatanl S; Hato T; Minamoto Y; Fujita S
Thromb Haemost; 1996 Dec; 76(6):1030-7. PubMed ID: 8972028
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.
Sung AD; Yen RC; Jiao Y; Bernanke A; Lewis DA; Miller SE; Li Z; Ross JR; Artica A; Piryani S; Zhou D; Liu Y; Vo-Dinh T; Hoffman M; Ortel TL; Chao NJ; Chen BJ
Radiat Res; 2020 Aug; 194(2):162-172. PubMed ID: 32845987
[TBL] [Abstract][Full Text] [Related]
18. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites.
Smith JW; Ruggeri ZM; Kunicki TJ; Cheresh DA
J Biol Chem; 1990 Jul; 265(21):12267-71. PubMed ID: 2373693
[TBL] [Abstract][Full Text] [Related]
19. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide.
Shmueli RB; Ohnaka M; Miki A; Pandey NB; Lima e Silva R; Koskimaki JE; Kim J; Popel AS; Campochiaro PA; Green JJ
Biomaterials; 2013 Oct; 34(30):7544-51. PubMed ID: 23849876
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
